Background: Subtotal lateral meniscectomy may lead to increased tibiofemoral contact pressures and early degenerative changes. Meniscal reconstruction using autograft tissue has been shown to restore load distribution and joint stability. This video demonstrates an arthroscopic technique for lateral meniscoplasty using a doubled semitendinosus tendon, combined with capsulodesis, to limit the meniscal extrusion rate. Indications: Patients with postmeniscectomy syndrome and a sufficient residual meniscal rim who present with lateral compartment pain and preserved articular cartilage. Technique Description: The patient is positioned supine with the leg hanging freely in a leg holder. Standard anteromedial and anterolateral portals are established. Capsulodesis is performed using two 3-mm PEEK implants placed on the lateral tibial plateau margin, creating shuttle sutures that secure the capsule. The semitendinosus tendon is harvested, doubled, and prepared as a 12 to 15 cm graft. Posterior and anterior tibial tunnels are drilled using a meniscal root guide and shuttle sutures are passed. The graft is introduced sequentially through these tunnels and positioned arthroscopically. Central fixation is achieved using all-inside sutures, with outside-in sutures securing the anterior horn. The tibial fixation is completed using PEEK interference screws. Results: The final arthroscopic inspection confirms anatomic graft positioning and congruent adaptation of the new graft to the lateral tibial plateau, restoring the meniscal contour. Discussion/Conclusion: Lateral meniscoplasty using a semitendinosus autograft combined with capsulodesis represents a biologic reconstructive option to restore the lateral meniscal rim and improve load transmission. Early biomechanical and clinical studies have demonstrated that semitendinosus autografts can function as viable meniscal substitutes, restore kinematics and improve joint contact pressures. Patient Consent Disclosure Statement: The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.
A variety of common and rare genetic factors have been implicated in the development of amyotrophic lateral sclerosis (ALS), and the evidence is that a genetic component is present in most affected individuals. However, our current understanding of ALS genetics causally explains only a small proportion of sporadic ALS, which accounts for over 90
Background: High-risk human papillomavirus (HR-HPV) infections with normal or low-grade cervical cytology are generally managed through observation because many infections clear spontaneously. However, persistent infection, particularly in women over 35 years of age, may increase the risk of progression and lead to prolonged surveillance, repeated examinations and patient anxiety. This study evaluates the effectiveness of local treatment with carboxymethyl β-glucan and polycarbophil (Colpofix®) in achieving negativization of high-risk (HR) human papillomavirus (HPV) in a Spanish population of women with HR-HPV positivity. Methods: This prospective, non-randomized controlled, multi-centre study enrolled 533 women aged 25–65 with HR-HPV and normal cytology, atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesions. Conducted in real clinical settings, it involved a 3-month treatment or ‘wait-and-see’ approach, with final follow-up at 6 months. Statistical analysis included various tests such as the Mann– Whitney test, Fisher’s exact test and Pearson’s χ2 test. Results: At 6 months, HR-HPV negativity was observed in 50.1% of treated patients compared with 24.0% in the observation group (p<0.0001). Higher clearance rates were recorded across all HR-HPV genotypes. For HPV16, negativization occurred in 50.7% of treated patients versus 9.2% of controls (p=0.0291). Resolution of cervical ectopy was more frequent in the treatment group (42.6% versus 11.5%, p<0.0001). No adverse events were reported. Conclusions: Local treatment with carboxymethyl β-glucan and polycarbophil was associated with higher rates of HR-HPV negativization and ectopy resolution compared with observation alone at 6-month follow-up, supporting its use as a management option, particularly in women over 35 years of age. Download the Plain Language Summary of this article: https://www.drugsincontext.com/plain-language-summaries/plain-language-summary-local-carboxymethyl-β-glucan-and-polycarbophil-in-women-positive-for-human-papillomavirus-a-prospective-observational-study
Abstract Introduction Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options. Masitinib, a tyrosine kinase inhibitor targeting microglial and mast cell activity in ALS pathogenesis, offers potential neuroprotection. This study presents a post-hoc analysis of long-term survivors treated with masitinib at 4.5 mg/kg/day in study AB10015, comparing observed survival to predicted and historical benchmarks. Methods Study AB10015 was a randomized, double-blind, placebo-controlled trial assessing masitinib with riluzole in ALS patients. Overall survival (OS) was measured from symptom onset to death, encompassing the double-blind period and post-study follow-up, including an optional, open-label program. The ENCALS model predicted survival of long-term survivors (≥5 years). A delay in the need for mechanical assistance, such as permanent ventilation, gastrostomy, tracheostomy, or wheelchair dependence, was used as a surrogate measure for quality of life (QoL). Results Among 130 patients receiving masitinib 4.5 mg/kg/day, the 5-year survival rate from onset was 42.3%, increasing to 50.0% in patients with an ALSFRS-R progression rate from disease onset of <1.1 points/month (AB10015 primary efficacy population) and 52.9% in a subgroup of patients without complete loss of functionality at baseline. Half of the long-term survivors had satisfactory QoL, defined as no mechanical assistance. The median OS for long-term survivors (n=55) was 121 months versus the ENCALS-predicted 42 months, yielding a 79-month residual median survival gain. Long-term survivors were prevalent across ALS baseline prognostic factors, including slow or moderate disease progression rate (ΔFS), severe or moderate functional severity, bulbar or spinal site of onset, respiratory function and age. Long-term survival was less likely in patients with complete loss of function at baseline or fast progressing disease (ΔFS ≥1.1 points/month) at baseline. Conclusions Masitinib treatment in ALS patients showed substantial survival benefit. Long-term survivors were largely independent of ALS prognostic factors, suggesting a subpopulation driven by microglial/mast cell activity. A recently identified biomarker detecting masitinib’s effect on pro-inflammatory microglia may help identify responsive patients.
BACKGROUND:The emergence of new multi-modular robotic surgical systems, such as Hugo RAS and Versius, introduces architectural and ergonomic variations compared with the established Da Vinci platform. While their surgical performance has been widely investigated, limited data exist regarding anesthesiological outcomes. This study aimed to compare intraoperative anesthetic parameters across three robotic platforms in a tertiary academic center. METHODS:A retrospective observational analysis was conducted on 258 consecutive patients who underwent robotic abdominal, urological, or gynecological surgery between January 2024 and June 2025. Patients were stratified according to the robotic platform used-Da Vinci, Hugo RAS, or Versius. Intraoperative variables, including Trendelenburg angle, anesthesia duration, pneumoperitoneum time, urine output, and fluid balance, were compared among groups. RESULTS:The Da Vinci system was used in 68.6% of cases, followed by Versius (15.9%) and Hugo RAS (15.5%). No major differences were observed in anesthesiological or postoperative outcomes across platforms, except for a higher intraoperative urine output with Versius in gynecological surgery. Minor variations included a steeper Trendelenburg position in colorectal surgeries performed with Da Vinci and shorter operative and pneumoperitoneum times with Versius in abdominal wall procedures. CONCLUSION:Despite structural and ergonomic differences, the Hugo RAS and Versius systems demonstrated anesthesiological safety and intraoperative performance comparable to the Da Vinci platform, supporting their safe integration into clinical practice.
